We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
<sup>90</sup>Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
- Authors
Abou-Nassar, K E; Stevenson, K E; Antin, J H; McDermott, K; Ho, V T; Cutler, C S; LaCasce, A S; Jacobsen, E D; Fisher, D C; Soiffer, R J; Alyea, E P; Koreth, J; Freedman, A S
- Abstract
Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more time for GVL effect to develop without the associated toxicity of a myeloablative HSCT. We performed a retrospective study to describe the outcomes of patients with relapsed, refractory or transformed FL who received yttrium-90 (90Y)-ibritumomab tiuxetan followed by fludarabine and low-dose BU RIC allogeneic HSCT at the Dana-Farber Cancer Institute between 2006 and 2009, inclusively. Twelve patients were identified with a median age of 55 (40-66) years and a median number of lines of therapy of 5 (2-10). Two patients (17%) had transformed to a more aggressive histology and five (42%) had chemorefractory FL. Cumulative incidences of grade II-IV acute GVHD at 100 days were 17% (±11%) and chronic GVHD at 12 months were 63% (±19%). Two-year non-relapse mortality was 18% (±12%). Two-year OS and PFS were 83% (±11%) and 74% (±13%), respectively. This treatment is associated with favorable outcomes including acceptable rates of GVHD and relapse in advanced FL patients, and warrants prospective studies.
- Publication
Bone Marrow Transplantation, 2011, Vol 46, Issue 12, p1503
- ISSN
0268-3369
- Publication type
Academic Journal
- DOI
10.1038/bmt.2010.339